Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Cigna Group pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common Stock Valuation Ratios
- Price to FCFE (P/FCFE)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cigna Group for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The financial metrics of the entity reveal specific trends and stability patterns over the analyzed periods. The debt to equity ratio exhibits moderate fluctuations, generally maintaining a range between 0.66 and 0.78. Notably, there is a gradual increase reaching the higher end of this spectrum in the most recent quarters, suggesting a slight rise in leverage relative to shareholders' equity.
The debt to capital ratio remains relatively stable, oscillating narrowly around 0.40 to 0.44 throughout the periods. This constancy indicates a steady proportion of debt within the overall capital structure, highlighting controlled debt levels in relation to total capital employed.
Similarly, the debt to assets ratio shows stability, hovering close to 0.21 to 0.22 for most periods, with a minor dip to 0.20 in later quarters. This suggests that the proportion of assets financed through debt has been consistently maintained, implying a balanced approach to asset financing.
Financial leverage has displayed a gradual upward trend, moving from approximately 3.16 to around 3.80. This increase indicates that the company is relying more heavily on debt financing relative to equity. The rising leverage may amplify returns but also elevates financial risk.
- Summary of Key Observations
- The company's capital structure is marked by modest increases in leverage, particularly visible in the debt to equity ratio and financial leverage metrics.
- Debt to capital and debt to assets ratios remain stable, implying steady use of debt within the overall financing mix and consistent asset coverage through debt.
- The upward trend in financial leverage suggests a strategic shift or an increased reliance on debt funding, which warrants monitoring for potential implications on financial risk.
Debt Ratios
Debt to Equity
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term debt | |||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q4 2024 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial trends reveals several key observations regarding the company’s debt, equity, and leverage levels over the past periods.
- Total Debt (US$ in millions)
- The total debt fluctuated moderately within the range of approximately 31,000 to 34,300 million over the observed timeframe. Initially, debt levels increased from around 31,972 million to a peak near 34,312 million in the third quarter of 2021 before gradually declining to just over 30,900 million by the end of 2022. Subsequently, the debt level experienced minor rebounds and decreases, maintaining a relatively stable pattern fluctuating around 31,000 to 32,700 million through the end of 2024.
- Shareholders’ Equity (US$ in millions)
- Shareholders’ equity experienced a general downward trend across the timeframe. Starting near 48,149 million in early 2021, equity values declined noticeably, falling below 45,000 million by the end of 2022. Although there were minor upticks in some quarters during 2023, the overall trajectory continued downward, reaching approximately 41,033 million by the close of 2024. This reduction indicates a erosion of equity capital over the period.
- Debt to Equity Ratio (ratio)
- The leverage ratio demonstrated an increasing trend, reflective of the changes observed in debt and equity. Beginning around 0.66 in early 2021, the ratio ascended gradually, crossing 0.7 and nearing 0.73 by multiple points in 2022 and 2023. Towards the end of the observed period, it further increased, peaking at 0.80 in early 2024 and settling slightly lower but still elevated near 0.78 by year-end 2024. This rise suggests an increase in financial leverage, potentially driven by the declining equity base paired with relatively stable debt levels.
Overall, the company’s financial condition shows a stable but moderately fluctuating debt profile, accompanied by a declining equity base, which results in increased leverage ratios over the period. This pattern warrants careful monitoring as higher leverage may imply elevated financial risk.
Debt to Capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term debt | |||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q4 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial metrics reveals several key trends in the debt and capital structure over the observed periods.
- Total Debt (in US$ millions)
- Total debt exhibited a generally fluctuating pattern, starting at 31,972 million at the beginning of the period. It increased moderately in the early quarters, peaking around mid-2021, then showed a gradual decline towards the end of 2022. Subsequently, total debt rose again in early 2023, followed by minor fluctuations through to the end of 2024, remaining within a range close to the initial level. These movements suggest an active management of debt levels without a consistent upward or downward long-term trend.
- Total Capital (in US$ millions)
- Total capital mirrored a generally declining trend over the period. Beginning from approximately 80,121 million, it showed minor variations in the initial quarters but experienced a noticeable decline starting mid-2022 through the end of 2024, dropping to a level around 73,000 million. This decline indicates a contraction in the overall capital base, potentially due to reductions in equity or retained earnings, or possibly asset base adjustments.
- Debt to Capital Ratio
- The debt to capital ratio maintained a relatively stable range between 0.40 and 0.44 throughout the period. Initially hovering around 0.40, it increased slightly to 0.42 during the mid-2021 to early 2023 period. From the first quarter of 2024 onwards, the ratio increased to approximately 0.44 and remained at that elevated level. This rise is consistent with the observed decrease in total capital while debt levels remained fairly stable, resulting in a higher proportion of debt financing relative to total capital.
Overall, the company demonstrated controlled variability in total debt, while total capital exhibited a downward trend, reflecting a shrinking capital base. The incremental increase in the debt to capital ratio towards the latter periods indicates a modestly higher leverage position. This pattern may warrant attention regarding future capital structure strategy and risk exposure.
Debt to Assets
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term debt | |||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q4 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals stability and minor fluctuations in the company's capital structure and overall financial position over the observed periods.
- Total Debt
- The total debt has exhibited relative stability with slight fluctuations. Starting at $31,972 million in March 2021, it increased moderately through mid-2021, peaking around $33,381 million in June 2022. Thereafter, a gradual decrease is apparent toward the end of 2022 and early 2023, with values declining to approximately $30,930 million by December 2022. The debt levels then rose again in 2023 and early 2024, fluctuating between roughly $31,900 million and $32,800 million. Despite these variations, the debt remained within a narrow range, indicating controlled management of liabilities within the company’s financial strategy.
- Total Assets
- Total assets displayed an overall incremental trend with some intermittent declines. Starting from $152,081 million in March 2021, assets moderately increased, reaching approximately $154,889 million by the end of 2021. During 2022, a dip occurred, dropping the total assets to about $143,932 million by December 2022, representing the lowest point in the observed timeline. Subsequently, the assets increased steadily throughout 2023 and into 2024, peaking near $157,639 million in September 2024 before a slight decrease to $155,881 million in the final quarter. This trend suggests periods of asset acquisition and divestiture, with an overall strengthening of asset base in the longer term.
- Debt to Assets Ratio
- The debt to assets ratio remained consistently stable, oscillating narrowly between 0.20 and 0.22 across the entire timeframe. This consistency reflects a balanced approach to leverage, indicating that the company's use of debt relative to its assets remained largely unchanged despite fluctuations in both debt and assets themselves. Notably, a slight decrease in the ratio was observed towards the latter part of 2023 and early 2024, suggesting a marginal improvement in financial leverage and potentially enhanced solvency.
In summary, the company maintained a steady capital structure over the examined periods, demonstrating prudent debt management and an overall growth trajectory in assets. The slight shifts in the debt to assets ratio underscore the company’s consistent risk profile in terms of financial leverage.
Financial Leverage
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q4 2024 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total Assets
- The total assets exhibited relative stability between 2021 and early 2022, fluctuating slightly around the 150 billion US dollar mark. A decline was observed in late 2022, dropping to approximately 144 billion US dollars. Subsequently, a gradual recovery trend occurred throughout 2023 and into 2024, with total assets reaching a peak near 157.6 billion US dollars in Q3 2024 before exhibiting a modest decrease by the end of 2024.
- Shareholders’ Equity
- Shareholders' equity demonstrated a downward trend starting in early 2021 from about 48.1 billion US dollars, decreasing steadily through 2022 to around 44.9 billion US dollars by year-end. During 2023, equity showed some recovery, rising to roughly 46.2 billion US dollars by Q4. However, in 2024 the level again fell significantly, ending the year at approximately 41.0 billion US dollars, which represents a notable decline compared to the initial periods.
- Financial Leverage
- Financial leverage increased consistently over the observed period. From a ratio of approximately 3.16 in Q1 2021, there was a gradual upward trend with minor fluctuations, reaching 3.3 by the end of 2022. The leverage ratio then accelerated more sharply during 2024, climbing from 3.72 in Q1 2024 to 3.8 by year-end, indicating a growing reliance on debt relative to equity over time.
- Overall Analysis
- The company’s asset base remained mostly stable with some fluctuations, while shareholders’ equity generally declined, especially sharply in 2024. This decline in equity combined with relatively stable or increasing assets has produced a rising financial leverage ratio, pointing to increased financial risk due to higher debt levels or lower equity cushions. The pronounced increase in leverage in 2024 suggests heightened exposure to financial obligations and potential vulnerability to adverse market conditions or operational challenges.